As of October 2, 2026, a Phase 4 clinical trial involving tirzepatide was listed with a status update on ClinicalTrials.gov. The trial, titled "GLP-1s to Enhance Lasting Optimal Weight," is registered under identifier NCT06861439. Its current status is active, not recruiting, meaning the study is ongoing but no longer enrolling new participants. The trial is designated as Phase 4, which typically refers to research conducted after a drug has received regulatory approval. Tirzepatide itself carries approved regulatory status. No results have been posted for this trial as part of this update. The data provided do not include information on trial design, participant numbers, endpoints, or expected completion date. This brief reflects only the status change recorded on the specified date and does not represent new findings or outcomes. Readers interested in the broader context of tirzepatide, including its approved uses and regulatory history, can consult the compound overview for additional background information.
Tirzepatide Phase 4 Trial "GLP-1s to Enhance Lasting Optimal Weight" Active
See the full tirzepatide overview
Source: https://clinicaltrials.gov/study/NCT06861439